Latest News
Cytokinetics Receives FDA Orphan Drug Designation for CK-2127107 for SMA
Cytokinetics, Inc. recently announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CK-2127107, a next-generation fast skeletal […]
Read More ›Cure SMA Announces 2017 Family Friendly Poster Session Presenters
We’ve recently seen significant advances in SMA research come to fruition, and with 17 drug programs in development, including five in clinical trials, we are invested to treating all ages, […]
Read More ›Cure SMA Awards $140,000 Grant to Alberto Kornblihtt, PhD, Universidad de Buenos Aires, Argentina
Cure SMA and FAME (Families of SMA, Argentina) have awarded a $140,000 research grant to Alberto Kornblihtt, PhD, at the Universidad de Buenos Aires, Argentina, for his project, “Epigenetics in […]
Read More ›RUSP Nomination for SMA Accepted into Evidence Review
The Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC) announced that they have accepted spinal muscular atrophy into the review process for the Recommended Uniform Screening Panel […]
Read More ›Cure SMA Welcomes Back Biogen as a National Premier Partner for 2017
Cure SMA is thrilled to welcome Biogen back as a National Premier Partner for 2017. The National Premier Partnership represents the highest level of support for the SMA community. As […]
Read More ›Cure SMA Awards $75,000 Grant to Yong-Chao Ma, PhD, Ann & Robert H. Lurie Children’s Hospital of Chicago
Cure SMA has awarded a $75,000 research grant to Yong-Chao Ma, PhD, Ann & Robert H. Lurie Children’s Hospital of Chicago, for his project, “Regulation of Motor Neuron Defects by […]
Read More ›